Open AccessMeta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza
Author(s) -
A.U. Sabitov,
О. П. Ковтун,
Н. А. Бацкалевич,
Н. И. Львов,
К. В. Жданов,
Е. В. Эсауленко,
Е. П. Тихонова,
Yu. S. Kalinina,
P. Sorokin,
С. В. Чепур,
А. В. Степанов
Publication year - 2021
Publication title -
antibiotiki i himioterapiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 11
ISSN - 0235-2990
DOI - 10.37489/0235-2990-2021-66-5-6-58-71
Subject(s) - medicine , randomized controlled trial , meta analysis , placebo , clinical trial , psychological intervention , systematic review , pediatrics , medline , alternative medicine , pathology , psychiatry , political science , law
The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin ® (Riamilovir) ecacy in etiotropic therapy of inuenza. Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a conrmed diagnosis of inuenza (with laboratory conrmed presence of inuenza virus antigens). Results. The conducted meta-analysis showed that the use of Triazavirin ® (Riamilovir) has a statistically signicant eect on the severity of clinical symptoms in patients with inuenza, therefore Riamilovir can be used in the initial therapy of adult patients with inuenza. Conclusion. Clinical studies have shown that the use of Triazavirin ® (Riamilovir) is eective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with inuenza. The meta-analysis of the collected data showed that therapy with Triazavirin ® (Riamilovir) has statistically signicant advantages in various aspects both in comparison with the placebo group and with the Tamiu ® (Oseltamivir) group.